Currently, the results of only 3 pilot studies of the drug BPC-157 without a control group, with a total of 30 participants, have been published.
Beneficial Compound-157 (BPC-157), commonly known in the fitness world as the “Wolverine peptide,” is synthesized from a molecule found in human gastric juice. 1. This compound is a 15-peptide with the chemical formula C₂H₃N₁O₂ . 2 .
BPC-157 has gained popularity on social media for its ability to accelerate the recovery of muscles, ligaments, and tendons after injections, with some bloggers claiming significant effects. Oral administration of BPC-157, because it is not easily destroyed by stomach acid, has the potential to restore the gastrointestinal lining. 3 However, BPC-157 is not yet FDA-approved and may be highly immunogenic; its purity, efficacy, and safety have also not been adequately studied. 4 Therefore, BPC-157 is classified as a Class II active pharmaceutical ingredient with restricted availability. 5 Currently, there is limited literature on human clinical studies of BPC-157. 6 Only three preliminary, uncontrolled studies have been published, with a total sample size of just 30 people. 6
Legal purchase of BPC-157 requires a prescription from a healthcare professional specializing in regenerative medicine and licensed to dispense pharmaceuticals. Following initial industry opposition, the FDA’s Prescribing Advisory Committee plans to review BPC-157′s use this summer to assess its feasibility for wholesale use.
However, because this peptide is classified as an experimental chemical, it can be purchased on numerous websites. This ease of availability leads people to take the peptide without consulting a doctor or considering potential side effects.
BPC-157 is most popular among young people and fitness enthusiasts, who believe this peptide can improve muscle recovery after intense workouts and reduce inflammation. While people expect BPC-157 to enhance athletic performance, the World Anti-Doping Agency (WADA) added it to its list of banned substances in 2022 .
Preclinical data suggest that BPC-157 may play multiple roles in several key signaling pathways. However, it should be noted that the receptor for BPC-157 has not yet been identified, and the data presented below are based on animal studies.
A 2025 literature review found that three studies reported no adverse reactions following BPC-157 injections in patients with intra-articular knee pain. However, the precise mechanism of action and long-term effects of BPC-157 in humans require comprehensive, large-scale clinical trials.
BPC-157 appears to stimulate angiogenesis and enhance blood flow via the VEGF signaling pathway. 9,10 Increased VEGFR2 phosphorylation activates other downstream pathways, such as PI3K, ERK1/2, and nitric oxide (NO). 6,11 These mechanisms may explain the rapid recovery after exercise due to increased blood flow to damaged muscles. BPC-157 can also activate the NO pathway via the Akt-eNOS axis. 11
BPC-157 is believed to phosphorylate focal adhesion kinase (FAK) and paxillin. This signaling pathway is responsible for regulating cell survival, migration, and adhesion. FAK binds to paxillin, allowing cell movement through cytoskeletal remodeling. Through this mechanism, cells can migrate to damaged areas of the body, promoting faster healing. 11,12
BPC-157 can reverse the paralyzing effects of neuromuscular blockers such as succinylcholine by stabilizing acetylcholine receptors at the neuromuscular junction. Through these synaptic functions, the peptide is believed to restore the neurotransmission effects observed after muscle injury. 12,13
Following administration of BPC-157, significant reductions in tumor necrosis factor-α, IL-6, and interferon-γ levels were observed. 12,14 This resulted in a shift in macrophage activity from M1 (proinflammatory) to M2 (reparative). 12,15 The analgesic effect may be achieved through modulation of neurotransmitters such as serotonin and dopamine. 14,15
Patients receiving BPC-157 reported local reactions following injection, such as redness, swelling, bruising, and pain. Because BPC-157 enhances the VEGF and NO pathways, dizziness and cardiovascular changes remain a concern for researchers. 11 Furthermore, angiogenesis, which is involved in the BPC-157-mediated repair mechanism, may promote tumor growth and cancer metastasis. 16 These and other potential systemic effects require large-scale clinical trials to determine safe and effective dosages. The effect of this peptide on individuals taking other medications or with comorbidities remains unclear.
Despite the promising therapeutic potential of BPC-157 in animal studies, insufficient validation of its pharmacokinetic and safety study methods remains an obstacle to optimizing its development. Given the availability and widespread use of BPC-157, it is recommended that the package insert clearly state the lack of human data to protect users and inform healthcare professionals of the potential risks of BPC-157 use.
Subscribe to Pharmaceutical Times to receive weekly clinical data summaries and stay up-to-date on the latest drug news, treatment recommendations, and trends in pharmaceutical practice.
Post time: Oct-16-2026